Rabih Chaer
Vascular Surgery · Stony Brook, NYNPI 1881648343
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.8%), grants and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Boston Scientific at 49.4% of the total. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $628.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$47K
- Medtronic$32K
- W. L. Gore & Associates, Inc.$9K
- Cook Incorporated$3K
- Cook Medical LLC$1K
- Penumbra, Inc.$1K
- plus $2K from 12 others
Across 45 payments — averaging $1436.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vesper Medical$22K
- Abbott$21K
- Philips North America LLC$5K
- W. L. Gore & Associates, Inc.$5K
- Cook Research Incorporated$5K
- Angiodynamics, Inc.$5K
- plus $2K from 1 others
What the payments were for
- Consulting fees$33,73036%
- Speaking & faculty fees$13,45014%
- Grants$30,20332%
- Travel & lodging$6,4887%
- Food & beverage$10,36411%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 49 | $46,520 |
| Medtronic(2 entities) | 14 | $31,807 |
| W. L. Gore & Associates, Inc. | 32 | $8,558 |
| Cook Incorporated | 1 | $2,550 |
| Cook Medical LLC | 26 | $1,438 |
| Penumbra, Inc. | 9 | $1,159 |
| Cook Research Incorporated | 1 | $401 |
| Abbott | 5 | $391 |
| Terumo Medical Corporation | 1 | $350 |
| Bolton Medical Inc | 3 | $201 |
| Inari Medical, Inc. | 1 | $184 |
| Johnson & Johnson | 1 | $156 |
| Vesper Medical | 1 | $149 |
| Bard Peripheral Vascular, Inc. | 2 | $134 |
| Cvrx, Inc. | 1 | $122 |
| Tactile Systems Technology Inc | 1 | $72 |
| Intact Vascular, Inc. | 1 | $28 |
| Angiodynamics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENDURANT IIS$30,325
- GENERAL - THERAPIES$15,111
- ANGIOJET$9,606
- Product in Development$5,437
- GENERAL VASCULAR INTERVENTION$3,000
- ELUVIA$2,692
- Zilver Vena$2,663
- JETSTREAM SC$2,336
- Endurant$698
- Indigo System$635
- GORE TAG Thoracic Endoprosthesis$599
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$573
- Zenith Alpha$511
- GORE VIABAHN Endoprosthesis with Heparin$410
- Penumbra System$395
- R2P MISAGO$350
- GORE VIABAHN VBX Balloon Expandable Endo$345
- GORE TAG Thoracic Branch Endoprosthesis$328
- GORE EXCLUDER AAA Endoprosthesis$325
- Zenith$252
How this compares
$94,241 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 27 | $21,496 |
| EliquisApixaban | 38 | $18,828 |
| ClopidogrelClopidogrel Bisulfate | 80 | $1,294 |
| Gabapentin | 33 | $408 |
| Prednisone | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $156 | $21,49627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in Stony Brook
- Apostolos TassiopoulosStony Brook$246K
- Angela KokkosisStony Brook$136K
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.5M
- Sonya NoorBuffalo$991K
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.